Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts

  • Boll, Lilian Marie
  • Vázquez Montes de Oca, Sergio
  • Camarena, Marta E.
  • Castelo Valdueza, Robert
  • Bellmunt Molins, Joaquim, 1959-
  • Perera Bel, Júlia
  • Albà Soler, Mar
Advanced bladder cancer patients show very variable responses to immune checkpoint inhibitors (ICIs) and effective strategies to predict response are still lacking. Here we integrate mutation and gene expression data from 707 advanced bladder cancer patients treated with anti-PD-1/anti-PD-L1 to build highly accurate predictive models. We find that, in addition to tumor mutational burden (TMB), enrichment in the APOBEC mutational signature, and the abundance of pro-inflammatory macrophages, are major factors associated with the response. Paradoxically, patients with high immune infiltration do not show an overall better response. We show that this can be explained by the activation of immune suppressive mechanisms in a large portion of these patients. In the case of non-immune-infiltrated cancer subtypes, we uncover specific variables likely to be involved in the response. Our findings provide information for advancing precision medicine in patients with advanced bladder cancer treated with immunotherapy., The work was supported by the following grants and agencies: 1. Research project PID2019-105595GB-I00 (R.C.) funded by MICIU/AEI/10.13039/501100011033 and PID2021-122726NB-I00 (MMA) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF: A way of making Europe”, by the “European Union”; 2. Project PI22/00171 (J.B.), funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union ; 3. 2021SGR00042 by Generalitat de Catalunya (MMA); 4. Ayudas Fundación BBVA a Proyectos de Investigación Científica en Biomedicina 2021 (MMA). LMB is funded by an INPhINIT PhD fellowship from “la Caixa” Foundation (ID 100010434), under the agreement LCF/BQ/DI21/11860060.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort

  • Camarena, Marta E.
  • Theunissen, Patrick
  • Ruiz, Marta
  • Ruiz Orera, Jorge, 1988-
  • Calvo Serra, Beatriz
  • Castelo Valdueza, Robert
  • Castro Alejos, Carla
  • Sarobe, Pablo
  • Fortes, Puri
  • Perera Bel, Júlia
  • Albà Soler, Mar
The expression of tumor-specific antigens during cancer progression can trigger an immune response against the tumor. Here, we investigate if microproteins encoded by noncanonical open reading frames (ncORFs) are a relevant source of tumor-specific antigens. We analyze RNA sequencing data from 117 hepatocellular carcinoma (HCC) tumors and matched healthy tissue together with ribosome profiling and immunopeptidomics data. Combining human leukocyte antigen-epitope binding predictions and experimental validation experiments, we conclude that around 40% of the tumor-specific antigens in HCC are likely to be derived from ncORFs, including two peptides that can trigger an immune response in humanized mice. We identify a subset of 33 tumor-specific long noncoding RNAs expressing novel cancer antigens shared by more than 10% of the HCC samples analyzed, which, when combined, cover a large proportion of the patients. The results of the study open avenues for extending the range of anticancer vaccines., This work was supported by the following grants and agencies: research projects PID2019-105595GB, PID2021-122726NB-I00, and PID2021-128791OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF: A way of making Europe” by the “European Union”; PI19/00004, PI20/00260, and PI22/00171, funded by Instituto de Salud Carlos III (ISCIII) and cofunded by the European Union and FEDER; 0011-1383-2019-000006 and 0011-1411-2021-000070, funded by Gobierno de Navarra; RTI2018-101759-B-I00 and the Instituto de Salud Carlos III, which finances Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREhd) and Red Española de Terapias Avanzadas TERAV ISCIII [RICORS: (RD21/0017), financed by the EU (NextGenerationEU, Plan de Recuperación Transformación y Resiliencia)]; AECC IDEAS20169FORT by Scientific Foundation of the Spanish Association Against Cancer; 2021SGR00042 by Generalitat de Catalunya; Ayudas Fundación BBVA a Proyectos de Investigación Científica en Biomedicina 2021; and European Reseach Council Advanced Grant NovoGenePop 101052538. Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort

  • Camarena, Marta E.
  • Theunissen, Patrick
  • Ruiz, Marta
  • Ruiz Orera, Jorge, 1988-
  • Calvo Serra, Beatriz
  • Castelo Valdueza, Robert
  • Castro Alejos, Carla
  • Sarobe, Pablo
  • Fortes, Puri
  • Perera Bel, Júlia
  • Albà Soler, Mar
The expression of tumor-specific antigens during cancer progression can trigger an immune response against the tumor. Here, we investigate if microproteins encoded by noncanonical open reading frames (ncORFs) are a relevant source of tumor-specific antigens. We analyze RNA sequencing data from 117 hepatocellular carcinoma (HCC) tumors and matched healthy tissue together with ribosome profiling and immunopeptidomics data. Combining human leukocyte antigen-epitope binding predictions and experimental validation experiments, we conclude that around 40% of the tumor-specific antigens in HCC are likely to be derived from ncORFs, including two peptides that can trigger an immune response in humanized mice. We identify a subset of 33 tumor-specific long noncoding RNAs expressing novel cancer antigens shared by more than 10% of the HCC samples analyzed, which, when combined, cover a large proportion of the patients. The results of the study open avenues for extending the range of anticancer vaccines., This work was supported by the following grants and agencies: research projects PID2019-105595GB, PID2021-122726NB-I00, and PID2021-128791OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF: A way of making Europe” by the “European Union”; PI19/00004, PI20/00260, and PI22/00171, funded by Instituto de Salud Carlos III (ISCIII) and cofunded by the European Union and FEDER; 0011-1383-2019-000006 and 0011-1411-2021-000070, funded by Gobierno de Navarra; RTI2018-101759-B-I00 and the Instituto de Salud Carlos III, which finances Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREhd) and Red Española de Terapias Avanzadas TERAV ISCIII [RICORS: (RD21/0017), financed by the EU (NextGenerationEU, Plan de Recuperación Transformación y Resiliencia)]; AECC IDEAS20169FORT by Scientific Foundation of the Spanish Association Against Cancer; 2021SGR00042 by Generalitat de Catalunya; Ayudas Fundación BBVA a Proyectos de Investigación Científica en Biomedicina 2021; and European Reseach Council Advanced Grant NovoGenePop 101052538. Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts

  • Boll, Lilian Marie
  • Vázquez Montes de Oca, Sergio
  • Camarena, Marta E.
  • Castelo Valdueza, Robert
  • Bellmunt Molins, Joaquim, 1959-
  • Perera Bel, Júlia
  • Albà Soler, Mar
Advanced bladder cancer patients show very variable responses to immune checkpoint inhibitors (ICIs) and effective strategies to predict response are still lacking. Here we integrate mutation and gene expression data from 707 advanced bladder cancer patients treated with anti-PD-1/anti-PD-L1 to build highly accurate predictive models. We find that, in addition to tumor mutational burden (TMB), enrichment in the APOBEC mutational signature, and the abundance of pro-inflammatory macrophages, are major factors associated with the response. Paradoxically, patients with high immune infiltration do not show an overall better response. We show that this can be explained by the activation of immune suppressive mechanisms in a large portion of these patients. In the case of non-immune-infiltrated cancer subtypes, we uncover specific variables likely to be involved in the response. Our findings provide information for advancing precision medicine in patients with advanced bladder cancer treated with immunotherapy., The work was supported by the following grants and agencies: 1. Research project PID2019-105595GB-I00 (R.C.) funded by MICIU/AEI/10.13039/501100011033 and PID2021-122726NB-I00 (MMA) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF: A way of making Europe”, by the “European Union”; 2. Project PI22/00171 (J.B.), funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union ; 3. 2021SGR00042 by Generalitat de Catalunya (MMA); 4. Ayudas Fundación BBVA a Proyectos de Investigación Científica en Biomedicina 2021 (MMA). LMB is funded by an INPhINIT PhD fellowship from “la Caixa” Foundation (ID 100010434), under the agreement LCF/BQ/DI21/11860060.